Beyond the Prostate: Rethinking Radiation Therapy for High-Risk Prostate Cancer
"Is It Time to Expand the Treatment Zone to Improve Outcomes?"
In the fight against prostate cancer, radiation therapy after surgery (radical prostatectomy) plays a crucial role, especially for men categorized as high-risk. Traditionally, this radiation, known as salvage radiotherapy (SRT), has been narrowly targeted at the area where the prostate used to be (prostate fossa). The idea was simple: hit the most likely spot for cancer recurrence.
However, limiting the radiation field might be a problem. Some research suggests that the cancer can spread to nearby lymph nodes in the pelvis, even if initial tests don't show it. This raises a key question: should SRT be expanded to include these pelvic lymph nodes, casting a wider net to catch any stray cancer cells?
A recent study delved into this issue by examining recurrence patterns in men with high-risk prostate cancer who received SRT that included the pelvic lymph nodes. By understanding where the cancer tends to reappear, researchers hoped to shed light on whether a more comprehensive approach to radiation therapy could improve outcomes.
Current Standards and Precision Techniques
For high-risk prostate cancer, gold-standard approaches include radical prostatectomy or radiation therapy combined with long-term androgen deprivation therapy. Precision radiotherapy is also described as a main radical-treatment method, and techniques include tomotherapy, which delivers radiation slice by slice, and CyberKnife, which tracks prostate position and corrects for movement during treatment. A 2025 analysis reported that MRI-guided stereotactic body radiation therapy using a 1.5-Tesla MR linear accelerator was feasible and safe. (Reference URL 1; Reference URL 2)
Radiotherapy’s Technical Turning Point
External-beam radiotherapy for prostate cancer came of age with the introduction of high-energy linear accelerators in the 1960s–1980s. Its use increased dramatically after PSA testing was introduced in the 1980s. Treatment dose was limited by side effects, particularly effects on the rectum, which constrained prostate cancer control. A review published in 2023 also summarized the history of prostate cancer diagnostics and treatment, focusing on the preceding 60 years.
Where Does Prostate Cancer Reappear After Salvage Radiotherapy?
The study looked at data from 196 high-risk prostate cancer patients who underwent SRT after their prostate was removed. All patients had experienced biochemical failure (BCF), meaning their PSA levels (a marker for prostate cancer) started to rise again after surgery, indicating the possible return of cancer. After SRT, 80 of these patients experienced another BCF, and 59 of them underwent imaging to find out where the cancer was recurring.
- Bone Metastases: The most frequent site, highlighting the systemic nature of some prostate cancer recurrences.
- Vesicourethral Anastomosis: Local recurrence at the surgical site, emphasizing the importance of adequate radiation coverage in this area.
- Lymph Nodes: Regional spread, suggesting the potential benefit of including pelvic lymph nodes in the radiation field.
Unresolved Questions About Pelvic-Nodal Radiation
The reported study identifies an evidence gap in high-risk prostate cancer: the efficacy of adjuvant or salvage radiation to regional lymph-node areas had not been fully investigated. It notes that radiotherapy was instead limited to the prostate fossa. The study’s title indicates that it examined recurrence patterns after salvage radiotherapy encompassing pelvic lymphatics, but the supplied summary does not provide its findings.
The Implications: Should Radiation Therapy Target a Wider Area?
This study's findings suggest that for some men with high-risk prostate cancer, expanding the radiation field to include the pelvic lymph nodes might be a good idea. Since most lymph node recurrences occurred outside the traditional radiation zone, a more comprehensive approach could potentially improve cancer control.
Real-World Outcomes and Economic Burden
Real-world evidence is relevant to shared decision-making: one study examined clinically relevant 10-year endpoints among men who received contemporary radiation therapy for localized prostate cancer. A separate US study used Optum claims and electronic health records from January 2010 through December 2021 to evaluate patient characteristics, treatment patterns, and outcomes in localized or locally advanced prostate cancer. Economic evidence remains limited, according to a 2026 study’s background, which describes post-treatment economic burden as an area with limited evidence. That analysis examined healthcare costs among Medicare beneficiaries treated initially with external-beam radiation therapy or radical prostatectomy.
However, it's not a one-size-fits-all situation. The study emphasizes the need to carefully select patients who might benefit most from this extended radiation field. Factors like the initial Gleason score (a measure of cancer aggressiveness) and pre-SRT PSA levels could help identify those at higher risk of lymph node involvement.
The authors conclude that while local recurrence at the anastomosis site remains a primary concern that might warrant dose escalation, elective pelvic nodal irradiation should be considered for selected individuals to optimize radiation therapy field.